Lv23
200 积分 2024-05-05 加入
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
2小时前
已完结
Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
23小时前
已完结
Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction
1天前
已完结
Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)
1天前
已完结
Nuclear transport proteins: structure, function, and disease relevance
2天前
已完结
Karyopherin-mediated nucleocytoplasmic transport
4天前
已完结
Selinexor: First Global Approval
4天前
已完结
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
4天前
已完结
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
4天前
已完结
皖公网安备34019202002308
